LONG-TERM FOLLOW-UP STUDY FOR PARTICIPANTS OF KITE SPONSORED INTERVENTIONAL STUDIES TREATED WITH GENE MODIFIED CELLS
- Registry ID
- KT-US-982-5968
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- KITE, A GILEAD COMPANY
- Last update
- 2022-04-11
Conditions
- B-CELL NON-HODGKIN'S LYMPHOMA
- NON-HODGKIN LYMPHOMA
- ACUTE LYMPHOBLASTIC LEUKEMIA
- DIFFUSE LARGE B-CELL LYMPHOMA
Related clinical trials
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
- A PHASE 1/2 OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF GSK5926371 IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
- A PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-1045 MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH NON-HODGKIN LYMPHOMA
- Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
- A MODULAR PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF AZD4512 MONOTHERAPY OR IN COMBINATION WITH ANTICANCER AGENT(S) IN PARTICIPANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
- AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS
View on source registry